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ABSTRACT 
Although there has been a recent renaissance in the availability of new 
therapeutic options for patients with acute myeloid leukemia (AML), 
survival rates remain low coupled with a high incidence of relapse. 
Enhancing T cell and immune function has become an effective 
therapeutic approach in hematological malignancies. However, AML cells 
can modulate the bone marrow microenvironment by changing 
extracellular nutrient and biochemical availability which can 
metabolically regulate immune function. Here we review the findings by 
Uhl et al. showing that T cell metabolism and function can be boosted by 
treatment with sodium bicarbonate to counteract the metabolic changes 
induced by lactic acid produced by leukemia cells. 
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INTRODUCTION  
Acute myeloid leukemia (AML) is an aggressive hematological 
malignancy arising from developmental arrest of cells of the myeloid 
lineage. The disease is characterized by a dominant clone of immature 
cells which rapidly accumulates in the bone marrow (BM) and peripheral 
blood resulting in the failure of normal hematopoiesis. The disorder is 
highly heterogeneous with distinct morphological, cytogenetic, and 
genetic abnormalities making the disease difficult to treat [1,2]. Clinical 
outcomes are generally poor, averaging around 45–50% survival at five 
years in younger patients (under 60 years) and 15–20% for those over 60 
years if treated with curable intent [3]. Clinical outcomes for AML patients 
have improved particularly for those individuals under 60 years. This is 
largely due to better supportive care, but an improved understanding of 
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relapse risk, greater availability of allogeneic hematopoietic cell 
transplantation (allo-HCT) and approval of several targeted therapies 
(particularly over the last 3 years) have also contributed [4]. However, up 
to 50% of AML patients relapse following allo-HCT depending on disease 
status and characteristics [5] and prognosis remains dismal at below 20% 
[6]. Thus, long term remission in AML is generally not durable and there 
is an urgent need to establish new treatments to prevent relapse. One 
approach is to improve the graft-versus-leukemia (GVL) effect. 
The recent study by Uhl et al. published in Science Translational 
Medicine has suggested that the failure of T cells in the allo-HCT recipient 
maybe related to impaired activation and metabolic activity of T cells 
imparted indirectly by the leukemia cells themselves [7]. To examine the 
links between T cell function, metabolic activity and AML relapse, the 
authors isolated T cells from AML patients who relapsed after allo-HCT 
and assessed metabolic fitness of CD8+ T cells. A profound reduction in 
glycolytic activity and oxidative phosphorylation was observed. 
Interestingly, using a murine model, culture of supernatant from leukemia 
cells with murine T cells was able to recapitulate reduction in metabolic 
fitness which was accompanied by reduced anti-tumor activity and 
suggest that a soluble factor was responsible. The concept that the 
metabolic state of the microenvironment is regulated by the activity of the 
leukemia (or cancer) cell is nothing new. Altering the availability of 
nutrients or chemicals within the microenvironment creates metabolic 
competition between immune cells, mesenchymal stromal cells (MSC) and 
cancer cells [8], with each cell utilizing the nutrients for different means 
(e.g., proliferation, DNA repair). For example, we recently showed that 
reactive oxygen species (ROS) which is inappropriately produced by 
NAPDH oxidase (NOX2) on the surface of AML cells, can alter AML cell 
metabolism to support proliferation [9]. In-deed, ROS can also affect anti-
tumor responses, acting as second messengers within T cells, controlling 
cell proliferation and clonal expansion ([10] and reviewed in [11,12]). 
Given the plethora of nutrients and chemicals produced by AML cells, it 
was therefore not surprising that changes in metabolites of AML cell and 
T cell culture supernatants were observed when analyzed by mass 
spectrometry. Uhl et al. noticed lactic acid levels to be highly abundant in 
the supernatant of leukemia cells in vitro when compared to control 
medium or supernatant derived from a T cell culture. The plasma of 
patients at primary AML diagnosis had lower levels of lactic acid and 
correlating CD8+ T cells exhibited a robust metabolic and cytokine profile 
compared to patients with AML relapse. Unfortunately, it was not tested 
what the levels of lactic acid were in de novo AML diagnostic samples 
compared to normal HSC or indeed the function of CD8+ T cells vs T cells 
from healthy individuals. Lactate levels have previously been shown to be 
increased in AML blasts at diagnosis [9] and acute leukemias [13]. 
Regardless, Uhl et al. showed significant increases in lactic acid in patients 
with AML relapse after allo-HCT but not in patients with AML who entered 
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remission following allo-HCT. The observed increases in lactic acid level 
were associated with acidification of the medium, lower pH and impaired 
T cell proliferative capacity and anti-tumor immunity. It was pleasing to 
see that that T cell proliferation was not affected by extracellular 
acidification when using hydrochloric acid, suggesting that acidification of 
the supernatant alone was not responsible for the observed effects of lactic 
acid. It was already known that high levels of lactic acid have an inhibitory 
effect on human T cell effector function [14] but it remains unclear 
whether the negative impact of lactic acid secreted by AML cells on T cell 
function is only found in the context of AML relapse following allo HCT, 
and if so why is this the case? 
To provide pre-clinical evidence of the efficacy of antagonizing 
metabolic acidosis in AML and the lactic acid induced effects on T cells, 
Uhl et al. aimed to assess T cell responses and leukemia development in 
vivo. To achieve this, the authors used a murine model coupled with 
sodium bicarbonate (NaBi; aka NaHCO3, baking soda or bicaNorm) 
treatment. Here AML bearing (WEHI-3B)-mice that underwent allo-HCT 
were administered NaBi. As expected NaBi did not have any direct toxic 
effects on AML cells in vivo. However, in the presence of T cells, the 
animals survived longer and had improved metabolic fitness and T cell 
function though syngeneic murine transplantation control experiments 
were not included here (and elsewhere in the study). Uhl et al. 
acknowledge the limitations of the murine model used in this study, 
though confirmatory studies were reproduced in the genetic FLT3-
ITS/MLL-PTD based GvL model. However, the study finishes with 
tantalizing data building on the above preclinical studies. Ten patients 
suffering from relapse following allo-HCT and received donor lymphocyte 
infusions were treated with oral NaBi (BicaNorm is clinically used to 
antagonize metabolic acidosis in patients) and improvements in metabolic 
and immune profiles of isolated T cells was observed. Whilst this approach 
seems promising, further discussion on the effects of BicaNorm treatment 
between donor T cells and autologous patient T cells were required. As 
stated above, high levels of lactic acid have an inhibitory effect on human 
T cell effector function [14], so it is not clear why Uhl et al. thought that 
lactic acid would negatively impact allogeneic donor T cells but not 
autologous patient T cells. Further, we are not confident on the clinical 
impact of NaBi treated patients in such a small study and as one would 
expect, the authors suggest that improved and more extensive clinical 
studies will need to be performed. It would be prudent to include in the 
trial patients who had not received allo-HCT and relapsed with AML. 
Further, given the heterogeneity in AML and subtypes that have metabolic 
alterations (e.g., IDH mutations), such studies will need to be on large scale 
to ensure appropriate power, especially considering that the defined 
group would be relapsing following allo-HCT.  
Whilst the study shows some correlation of lactic acid levels with CD8+ 
T cell function/activity, the BM microenvironment is a complex tissue; in 
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addition to tumor and the extracellular matrix, the HSC niche may 
comprise different cell populations such as MSC, endothelial cells, 
osteoblasts as well as progeny of HSCs and other immune cell subtypes (NK 
cells, CD4+ T cells, regulatory T cells, γδT and iNKT cells etc.). It remains to 
be understood what the role of increased lactic acid levels are in this 
complex environment regarding re-invigorating immune function and 
affects AML blast survival. Further, mechanistically, whilst the authors 
show reduced glycolytic activity in AML correlates with lactate release, 
further insight into this mechanism may provide additional therapeutic 
targets. For example, it would be interesting to determine whether 
targeting the pathways that lead to increased lactate levels is also a viable 
alternative in AML patients following allo-HCT and relapse. 
Monocarboxylate transporters (MCT) are responsible for transmembrane 
lactate trafficking, with MCT1 involved in both import and export, MCT2 
import and MCT4 primarily export of lactate, with all these isoforms 
reported to be overexpressed in different tumors (reviewed in [15]). Here, 
inhibiting T cell uptake of lactic acid using MCT1 inhibitor led to 
normalization of glycolytic activity comparable to untreated T cells. 
Indeed, many of the effects of lactate on T cell immune function can be 
recapitulated through modulating MCT activity and again provide 
alternative strategies to antagonize the acidosis in the patient.  
In conclusion, the study of Uhl et al. highlights the importance of 
relapse in AML following allo-HCT. They present compelling data that 
provide a pharmacological strategy to enhance GvL effects in patients 
relapsing following allo-HCT. The data shows that treatment using sodium 
bicarbonate overcomes metabolic reprogramming of transferred T cells to 
improve tumor control (Figure 1). It is interesting to speculate that in the 
right context, treatment with sodium bicarbonate or agents that improve 
immune metabolic fitness may augment current therapies such as CAR-T 
[16], checkpoint inhibition [17], or blockade of immunosuppressive “don’t 
eat me signals” [18] and ultimately further improve AML patient outcome. 
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Figure 1. Potential effects of sodium bicarbonate treatment on immune cells in an AML lactic acid producing 
environment following an allogeneic hematopoietic cell transplant (HCT). The mechanisms for T cell 
metabolic boost are based on findings from Uhl et al. [7]. Following an allo-HCT, elevated lactic acid levels 
produced by AML blasts in the BM microenvironment decreases T cell intracellular pH and impairs 
metabolic fitness of T cells; effects are restored by sodium bicarbonate treatment leading to improved T cell 
fitness and function and further metabolism of additional lactic acid into the tricarboxylic acid cycle (TCA). 
Uhl et al. focused on CD8+ T cell function, but effects of sodium bicarbonate treatment on other immune 
subtypes and BM microenvironment are not currently known. 
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